Independent Study Presented at American Society of Hematology Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD Iron Investing
LABRADOR IRON ORE ROYALTY CORPORATION - CASH DIVIDEND FOR THE FOURTH QUARTER OF 2025 - $0.35 PER COMMON SHARE Iron Investing
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue Iron Investing
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids Iron Investing
